Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma
Status:
Completed
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and the best dose of brentuximab vedotin when
given together with gemcitabine hydrochloride and to see how well they work in treating
younger patients with Hodgkin lymphoma that has returned or does not respond to treatment.
Monoclonal antibodies, such as brentuximab vedotin, may find cancer cells and help kill them.
Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop
the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Giving brentuximab vedotin together with gemcitabine hydrochloride may kill more cancer
cells.